Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.
New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, found that rheumatoid arthritis (RA) patients in sustained remission who stopped TNF inhibitors (TNFi) had significantly more flares and lower Boolean 2.0 remission rates compared with those who continued treatment.
TNF Inhibitor Tapering Raises Flares, Cuts RA Remission Rates miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.